January 18, 2026, 4:43 PM EST. Medtronic (MDT) is trading on the prospect that a planned stand-alone spin-off of its diabetes business will sharpen focus on B2B operations and lift margins. Management has signaled the split should close by year-end 2026, reducing exposure to consumer diabetes care, which generated about 8% of revenue but only 4% of operating profit in fiscal 2025. A new growth driver comes from the Hugo robotic-assisted surgery (RAS) system, cleared in the U.S. for urologic procedures. While near-term top-line impact is modest, the device targets an underpenetrated market with long-term potential. Finally, Medtronic boasts a lengthy dividend streak, raising payouts for 48 consecutive years and offering about a 3% forward yield, with the potential to join the Dividend King club after 50 straight raises.